Lilly ' s Jardiance Meets Main Goal in Type 1 Diabetes Patients Lilly ' s Jardiance Meets Main Goal in Type 1 Diabetes Patients
Eli Lilly& Co said on Monday that its drug Jardiance (empagliflozin), along with insulin therapy, met the main goal of two trials testing it in patients with type 1 diabetes, a population for which it is not presently approved.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
More News: Diabetes | Diabetes Type 1 | Empagliflozin | Endocrinology | Health | Insulin | Jardiance